PRF Technologies clears IND for OcuRing-K Phase II cataract trial

The Israel-based dual-business company reported FDA IND clearance for its intraocular drug-delivery ring and positive preclinical data for its non-opioid pain

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A clear, circular medical implant and silver surgical tweezers rest on a light blue sterile drape in a brightly lit medical setting.

PRF Technologies (Nasdaq: PRFX), a Tel Aviv-based company straddling pharmaceutical drug delivery and AI-driven energy software, has published its first-half 2026 business update highlighting two clinical milestones alongside continued commercial expansion of its DeepSolar energy platform.

The company's most significant healthcare development was FDA clearance in April 2026 of the investigational new drug application for OcuRing-K, a bio-erodible intraocular ring developed through its majority-owned subsidiary LayerBio. The device is designed to deliver ketorolac in a single intraoperative application, releasing the anti-inflammatory agent locally over the post-surgical period. PRF says the aim is to replace the multi-drop eye-drop regimens that routinely follow cataract surgery, which the company argues carry well-documented compliance problems. Patient enrolment in a multi-centre US Phase II trial evaluating pain, inflammation and safety is expected to begin in the second half of 2026.

Pain pipeline shows preclinical promise

PRF's second healthcare programme, PRF-110, reported comparative preclinical results in May and June 2026. In a head-to-head study conducted in a validated porcine model, the extended-release ropivacaine formulation matched ZYNRELEF (bupivacaine and meloxicam extended-release solution, marketed by Heron Therapeutics) on 72-hour analgesic activity. Expanded data from the same study indicated slower systemic absorption and enhanced retention at the surgical site. PRF is positioning PRF-110 as an NSAID-free, non-opioid post-surgical analgesic, a profile it says differentiates the candidate from combination products currently on the market.

The non-opioid analgesic segment is attracting considerable pharmaceutical attention as US payers and regulators continue to press for alternatives to opioid-based acute pain management. Extended-release local anaesthetics and drug-device combination products represent one of the more active subsectors. Heron's ZYNRELEF, the benchmark PRF selected for its head-to-head study, itself only received FDA approval in 2021, suggesting the market is still developing. Preclinical porcine model data, while useful for characterising pharmacokinetic behaviour, are not predictive of human outcomes, and PRF has not disclosed a timeline for IND-enabling work or Phase I trials in PRF-110.

Financial position and the energy arm

PRF ended June 2026 with approximately $11.6 million in cash and short-term deposits, nearly triple its position at year-end 2025, following a $10 million raise under a standby equity purchase agreement completed in May. Net loss for the half-year was approximately $2.8 million, slightly wider than the $2.3 million loss recorded in the equivalent period of 2025. The company reduced general and administrative costs by 39% year-on-year while almost tripling research and development expenditure, though R&D remained modest in absolute terms at approximately $0.8 million.

On the energy side, the company's DeepSolar subsidiary validated its Predict AI platform using real-world European utility data, launched GridFeed as an energy trading optimisation product, and began recognising revenue from commercial engagements including a SaaS agreement with Shikun and Binui Energy at a 71 MW solar site in Romania and a due diligence engagement with EDF Power Solutions Israel.

Interim chief executive Efraim Cohen-Arazi said the half-year "delivered two important advances: a significant regulatory milestone and compelling comparative data," adding that the company enters the second half with "two distinct value drivers."

PRF's dual-business structure is unusual in a listed biotech context. Investors will need to assess whether the capital and management bandwidth a small-cap company of this scale can deploy across ophthalmic drug delivery, post-surgical pain and AI energy software is sufficient to advance any single programme to a value-inflecting milestone. The Phase II OcuRing-K enrolment timeline and further PRF-110 preclinical readouts in the coming quarters will be the primary indicators of healthcare execution.

Sector

Topic

Geography